News
-
-
-
-
-
-
PRESS RELEASE
Zentiva secures approx. 85.27% of APONTIS PHARMA AG voting rights in the context of its public purchase offer
Zentiva AG, a subsidiary of Zentiva Pharma GmbH, secures approx. 85.27% of APONTIS PHARMA AG voting rights in a successful public purchase offer, aiming to enhance medicine delivery capabilities -
-
-
PRESS RELEASE
Condition of minimum acceptance in Zentiva’s Voluntary Public Purchase Offer waived – Acceptance Period remains unchanged and ends on 21 November 2024 at 24:00 CET
Zentiva AG waives minimum acceptance condition in APONTIS PHARMA purchase offer, maintaining original timeline. Significant shareholder acceptance received -
